ArticleThe Lancet regional health. Western Pacific2026
Efficacy and safety of minocycline on patients with acute anterior circulation ischaemic stroke undergoing mechanical thrombectomy (MIST-A): a multicentre, prospective, randomised, open-label, blinded-endpoint, phase 2 trial.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05487417 (Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Minocycline has anti-inflammatory and neuroprotective properties. Prior clinical trials have shown potential benefits in acute ischaemic stroke (AIS), but its efficacy in patients who achieve successful reperfusion with mechanical thrombectomy (MT) remains unknown. Methods: This multicentre, prospective, randomised, open-label, blinded-endpoint, phase 2 trial was conducted at eight hospitals in China. Patients with ischaemic stroke due to anterior circulation large-vessel occlusion who achieved successful recanalisation after MT were randomly assigned (1:1) via a centralised web-based system to receive either oral minocycline (100 mg twice daily for 5 days) as an adjunct to standard care or standard care alone. The primary outcome was the infarct growth ratio (day 5 infarct volume divided by baseline infarct volume), analysed in the modified intention-to-treat population (mITT). This trial was registered at ClinicalTrials.gov, NCT05487417. Findings: Between Nov 21, 2022, and June 9, 2025, 189 patients were randomly assigned. After excluding two patients due to major protocol violations, 187 patients were included in the mITT analysis (94 minocycline, 93 control). The median day 5 infarct growth ratio was 1.8 (IQR 1.3-3.3) in the minocycline group and 1.6 (IQR 1.2-2.8) in the control group, yielding an adjusted geometric mean ratio of 1.10 (95% CI 0.84-1.45; p = 0.49). At day 90, 68.1% (64/94) in the minocycline group versus 72.0% (67/93) in the control group achieved functional independence (modified Rankin Scale score 0-2; adjusted risk ratio 1.00, 95% CI 0.70-1.43). There were no significant differences between the minocycline group and control group in the incidence of adverse events (76.6% [72/94] vs 68.8% [64/93]) or serious adverse events (25.5% [24/94] vs 25.8% [24/93]). Interpretation: In patients with AIS successfully treated with MT, adjuvant minocycline did not reduce infarct growth. The safety profile of minocycline was similar to that of standard care. These findings do not support the use of minocycline as a neuroprotective therapy in this specific population of patients. Funding: Noncommunicable Chronic Diseases-National Science Technology Major Project; Shaanxi Province Special Support Program for Leading Talents in Scientific and Technological Innovation; Xijing Hospital Medical Personnel Training and Development Program; Shaanxi Provincial Health Commission Cerebrovascular Disease Scientific Research Innovation Team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.